百濟神州 PD-1 抑制劑替雷利珠單抗在日本獲准，挑戰全球製藥巨擘
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
2026年2月12日
2 min read
BeiGene SEC Filing
規範來源China / Japan
完整分析75%
核心变化
百济神州PD-1抑制剂替雷利珠单抗获日本厚生劳动省批准，用于治疗非小细胞肺癌，标志其进入日本市场。
Source Report
百济神州的抗 PD-1 抗体替雷利珠单抗获得日本厚生劳动省批准，用于治疗非小细胞肺癌。
Sigvera Intelligence
核心要點
1Japanese MHLW approval for tislelizumab in non-small cell lung cancer
2First Chinese-developed PD-1 inhibitor approved in Japan
3Directly competes with Keytruda and Opdivo in the Japanese market
Strategic Implications
Market Impact
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
Industry Context
健康科技与生物技术
Where this signal fits in the broader landscape.
41 条行业信号监管
Company Activity查看全部
Source Verification
Verified from official source
PublisherBeiGene SEC Filing
發佈日期Feb 12, 2026
來源類型Exchange Filing
來源分類Verified Canonical
信号时间线
首次报道Feb 12, 2026
索引时间Feb 13, 2026
发布时间Feb 14, 2026
https://pj.jiho.jp/article/253329
Read Full Source置信度:95%
Get cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
登录